エピソード

  • RXRX Today - Jul 15: Small Gain Amid Buzz

    RXRX Today - Jul 15: Small Gain Amid Buzz
    2026/07/15
    Hey there! It’s Joey here, your friendly longtime investor, breaking down the day for you. Today we’re talking about Recursion Pharmaceuticals, ticker RXRX. It was a green day, up about 1.2%.

    So, what went down? RXRX saw a bit of a bounce today, not huge, but hey, any gain is better than a loss, right? The stock traded a bit under its usual volume, which is kinda interesting.

    Now, why the little bump? Well, there’s a couple of things buzzing around. First off, some chatter about the company reaching an “inflection point.” Sounds fancy, but basically, it means they’re hitting a turning point that could lead to some good things. Plus, Cathie Wood, you know her, right? She’s been loading up on RXRX, which gets people talking. When a big name like that backs a stock, it can stir up some excitement.

    There’s also been some positive vibes about their Q4 results, which is always a good thing. Investors love to see companies beating expectations. So, a combo of Cathie’s interest and some good numbers seems to have given RXRX a little boost today.

    Oh, and one thing to keep in mind: Recursion’s been making some noise in the biotech space. They’re working on some pretty innovative stuff, so the chatter isn't just noise; it could lead to something significant down the road.

    That’s the scoop for today! RXRX managed to hold its ground with a slight gain, and with all this buzz, it’s definitely worth keeping an eye on. Just remember, I’m here to share info and keep things fun, not to give financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • RXRX Today - Jul 14: Cathie Wood's Interest Sparks Buzz

    RXRX Today - Jul 14: Cathie Wood's Interest Sparks Buzz
    2026/07/14
    Hey there! It's Joey here, your friendly neighborhood investor, ready to break down what went down with Recursion, or RXRX, today. Spoiler alert: it was a red day, down almost 2%. Ouch!

    So, here’s the scoop. RXRX started the day with some serious hype, thanks to some buzz around Cathie Wood. You know her—she's the big-name investor who’s always making waves. People were super excited about her interest in the stock, thinking it might be a no-brainer buy. But as the day went on, folks started hitting the sell button pretty quickly. The volume was way below average, which usually means people were feeling a bit cautious.

    Now, why did it go down? Well, there’s a mix of reasons. Some chatter in the air said that while Cathie loading up on RXRX is great, it doesn’t erase the fact that the stock has been struggling for a while. It’s kind of like when your favorite band drops a new album, but you realize it’s not as good as the last one. People want to see more than just hype; they want results. Plus, there were articles floating around that mentioned RXRX still isn’t worth buying just yet, which probably made some investors think twice.

    Also, it’s worth mentioning that the stock saw a little pre-market surge after a report about a strong Q4, with the CEO saying they’ve reached an inflection point. But as we saw, that didn’t hold up throughout the day. So yeah, a bit of a rollercoaster for RXRX.

    Looking ahead, one thing to keep in mind is that there’s a Form 144 filing that came out recently. That’s usually a signal for investors to pay attention, as it can mean insiders are selling shares. It’s a mixed bag for sure.

    So, to wrap it up, RXRX had a bit of a wild ride today. Cathie Wood’s interest got people hyped, but the reality check hit hard as the day went on. Just remember, this is all for your info and entertainment, not financial advice. Stay savvy out there, and catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Jul 13: Stock Takes a Dip

    RXRX Today - Jul 13: Stock Takes a Dip
    2026/07/13
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Recursion, or RXRX, today. Spoiler alert: it was a red day. The stock slipped by about one and a half percent. Ouch!

    So, what happened? Well, RXRX got smoked today, dipping down a bit. You could say it was a slow bleed, and honestly, it didn’t get a ton of love from the market. There was a decent amount of trading, but it was way below the usual volume. People seemed to be hitting the sell button pretty quickly.

    Now, why did this happen? It looks like there’s some chatter about whether the stock is fully priced. An article from Simply Wall Street pointed out that while the company is making strides in its clinical progress, some folks are questioning if the current price reflects its true value. That uncertainty can scare investors off. Plus, there’s a piece from the Motley Fool calling out RXRX and other stocks as beaten-down but not worth buying right now. When you hear that kind of talk, it can definitely shake up confidence.

    On the flip side, Cathie Wood just made some moves, snagging a few stocks that she thinks are bargains. But it’s unclear if RXRX made her shopping list. So, while some big names are out there hunting for deals, it seems like RXRX was left behind today.

    Just a quick heads up: Recursion is still pushing through its clinical trials, which could be a game-changer if things go well. So, keep an eye on that, ’cause it could shift the narrative if they hit some big milestones down the line.

    Alright, that wraps it up for today! RXRX had a rough day, but that’s how the market rolls sometimes. Remember, this is just info for you to chew on, not financial advice. Stay savvy out there, and I’ll catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Jul 12: Stock Takes a Hit

    RXRX Today - Jul 12: Stock Takes a Hit
    2026/07/12
    Hey there! It’s Joey, your friendly neighborhood investor. Today, we’re talking about Recursion, ticker RXRX. It was a red day for them, down about 5.3%. Ouch!

    So, what went down? The stock got smoked today, dropping after a pretty rocky couple of days. People were hitting that sell button hard. There was a lot of chatter around its clinical progress, but it seems like investors weren't super impressed. You know how it goes; sometimes, no matter how much potential a company has, if the vibes aren’t right, it can lead to a rough day.

    Now, why did this happen? Well, a couple of articles pointed out that while Recursion is making strides in the biotech space with its AI-driven approach, folks are still questioning whether it’s fully priced. Sounds like investors are a bit wary about how much future growth is already baked into the stock price. Plus, some analysts are still seeing it as a beaten-down stock that isn't quite ready to bounce back. It’s like they’re waiting for a sign or something, but right now, it feels like they’re just sitting on their hands.

    And hey, there’s also some buzz around the broader AI landscape. A couple of articles mentioned that Recursion and similar stocks might still have some contrarian investors eyeing them, especially since they're considered undervalued. So, while today was rough, there’s still some talk about potential down the line.

    Wrapping it up, Recursion's having a tough time today, but keep an eye out. The biotech world is always changing, and what looks bad now might flip around later. Just remember, I’m here for info and entertainment, not to give you financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Jul 11: Insider Selling Spooks Investors

    RXRX Today - Jul 11: Insider Selling Spooks Investors
    2026/07/11
    Hey there, it's Joey! I've been investing for a while and today, we're breaking down Recursion, or RXRX. It was a rough day for the stock, down about 5.3%. Ouch!

    So, what happened? RXRX got smoked today, and it wasn't just a little dip. The stock slid after some insider selling news hit the wires. Blake Borgeson, a director at Recursion, dumped 40,000 shares for about $158,500. Yeah, that one stung. When insiders sell, it usually raises eyebrows, and today was no different. Investors hit that sell button fast, sending the stock down.

    Now, let’s chat about the why. There’s been a lot of chatter lately about Recursion’s potential in the biotech and AI space. Just yesterday, there were some positive vibes with the stock soaring pre-market after they reported beating earnings in Q4. The CEO even said they reached an “inflection point,” which sounds super promising, right? But then, bam, this insider selling pops up, and people start to panic. It’s like, one step forward, two steps back.

    Also, on top of all that, there’s been buzz about RXRX being seen as one of those penny stocks that some big names are keeping an eye on. But with this selling news, it feels like that hype took a hit. So, you’ve got this mix of potential and caution swirling around.

    One thing to keep in mind is that the volume today was pretty high, but it was still below the average. So, a lot of folks were watching, but maybe not as many were buying. Just something to think about.

    Alright, that's the scoop on Recursion today. Stocks can be wild and unpredictable, and this one’s no exception. Just remember, I’m here to keep you informed and entertained, not to give financial advice. Take care, and catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Jul 10: Insider Selling Hits Stock

    RXRX Today - Jul 10: Insider Selling Hits Stock
    2026/07/10
    Hey there! It's Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we're talking about Recursion Pharmaceuticals, or RXRX for short. Spoiler alert: it was a red day today. The stock got smoked, dropping about 7.6%. Ouch.

    So, what went down? Well, the stock started off strong pre-market, even soaring at first after some positive Q4 news and the CEO hyping up that the company hit an “inflection point.” Sounds cool, right? But then, things took a turn. The energy fizzled out as news broke that one of the directors, Blake Borgeson, sold off a hefty chunk of his shares—40,000 to be exact. That’s about $158,500 worth. Yeah, that one stung for investors. When you see insiders selling, it kinda makes you wonder. Like, are they not feeling so hot about the future?

    Now, why did this happen? The buzz was all about that initial good news, but then the sell-off from Borgeson threw a wet blanket over the excitement. Investors started hitting the sell button fast, probably feeling a bit uneasy about what this insider move meant for the company’s future. Plus, the volume was way below average for the day, which tells you that folks were either scared or just not buying what they were selling.

    Looking ahead, keep in mind that Recursion’s been pushing hard in the AI space, so they might have some interesting updates coming. But with today’s action, it’s clear people are on edge.

    So, that’s the scoop on RXRX. It’s a wild ride, as always! Remember, I’m just here to share what I see, not give advice on what you should do with your cash. Stay curious and keep it fun out there!
    続きを読む 一部表示
    2 分
  • RXRX Today - Jul 09: Recursion's Green Day

    RXRX Today - Jul 09: Recursion's Green Day
    2026/07/09
    Hey there! I’m Joey, your go-to guy for stock talk, and I’ve been in the investing game for a while. Today, we’re chatting about Recursion, and guess what? It had a green day, up about 4.5%. Not too shabby!

    So, here’s the scoop. RXRX started the day on a bit of a rollercoaster but ended up finishing strong. It seems like there was some buzz around it that got folks excited. Volume was pretty high, but honestly, it’s still way below the average. Kinda like when you’re super hyped for a concert, but the venue is half-empty. You feel me?

    Now, why did it pop today? Well, there’s been some chatter about Recursion gaining a bit of credibility thanks to its expanded presence in the Russell Index. That’s like getting a gold star in the stock world. People might be feeling more confident about the company, which is always a good vibe. Plus, there was some strong call option sentiment floating around before the market opened. Looks like some traders were betting on RXRX to keep pushing up, and hey, it kinda worked!

    Oh, and one quick thing to keep in your back pocket—Recursion’s been making moves, and it’s all about that AI and biotech crossover. They’re trying to carve out a niche in the big ol’ healthcare space, so keep an eye on that.

    Alright, that’s a wrap for today! RXRX had a nice little bounce, and who knows what’s next? Just remember, I’m here for the info and fun, not to tell you where to put your cash. Catch you later!
    続きを読む 一部表示
    1 分
  • RXRX Today - Jul 09: Gaining Strategic Credibility

    RXRX Today - Jul 09: Gaining Strategic Credibility
    2026/07/09
    Hey there! It’s Joey, your go-to guy for stock talk. I’ve been investing for a while, and today we're checking out Recursion, ticker RXRX. It was a green day, up about 4.5%. Not too shabby!

    So, what went down? RXRX moved up a bit, but honestly, it felt like a slow day overall. Volume was way below average. People were trading like they were stuck in neutral. But hey, a gain is a gain, right?

    Now, why did this happen? Well, there’s some buzz about Recursion gaining some serious credibility after getting expanded into the Russell Index. That’s like the cool kids' table for stocks. Being in that index can help attract more investors and legitimize the company in the eyes of the market. Plus, there’s been chatter about strong call option sentiment, which usually means folks are feeling optimistic about the future. But, to be real, nobody's exactly sure why it was such a low-volume day. Just one of those things, I guess.

    Looking ahead, they recently filed Form 144, which is basically a notice for selling shares. It could mean something’s brewing, so keep an eye on that.

    Alright, that’s the scoop on RXRX today. Just remember, I’m here to share info and have some fun with the stock chat, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分